Cencora, Inc. $COR Shares Purchased by Graham Capital Management L.P.

Graham Capital Management L.P. raised its stake in shares of Cencora, Inc. (NYSE:COR) by 95.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 21,715 shares of the company’s stock after purchasing an additional 10,615 shares during the period. Graham Capital Management L.P.’s holdings in Cencora were worth $7,334,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Oakworth Capital Inc. acquired a new position in Cencora during the fourth quarter worth approximately $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora in the fourth quarter worth $27,000. Archer Investment Corp increased its position in shares of Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after acquiring an additional 47 shares in the last quarter. Motiv8 Investments LLC acquired a new stake in shares of Cencora in the fourth quarter worth $29,000. Finally, IAG Wealth Partners LLC acquired a new stake in shares of Cencora in the third quarter worth $30,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Price Performance

Shares of COR stock opened at $281.22 on Wednesday. The company has a market capitalization of $54.71 billion, a PE ratio of 21.57, a price-to-earnings-growth ratio of 1.52 and a beta of 0.59. The firm has a fifty day simple moving average of $287.49 and a 200-day simple moving average of $326.05. The company has a current ratio of 0.95, a quick ratio of 0.59 and a debt-to-equity ratio of 3.40. Cencora, Inc. has a twelve month low of $244.82 and a twelve month high of $377.54.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, May 6th. The company reported $4.75 earnings per share for the quarter, missing the consensus estimate of $4.82 by ($0.07). The firm had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. Cencora had a net margin of 0.78% and a return on equity of 135.20%. Cencora’s revenue for the quarter was up 3.9% compared to the same quarter last year. During the same quarter last year, the company posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Equities research analysts anticipate that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its board has approved a share buyback plan on Thursday, May 21st that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 3.9% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.

Cencora Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, June 1st. Shareholders of record on Friday, May 15th were paid a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 0.9%. The ex-dividend date was Friday, May 15th. Cencora’s dividend payout ratio is 18.40%.

Analysts Set New Price Targets

Several research firms have recently issued reports on COR. Citigroup dropped their price objective on shares of Cencora from $405.00 to $355.00 and set a “buy” rating for the company in a research report on Thursday, May 7th. Weiss Ratings lowered shares of Cencora from a “buy (b)” rating to a “buy (b-)” rating in a research report on Friday, May 22nd. Morgan Stanley set a $342.00 price objective on shares of Cencora in a research report on Friday, May 8th. William Blair began coverage on shares of Cencora in a research report on Tuesday, April 28th. They issued a “market perform” rating for the company. Finally, Evercore set a $360.00 price objective on shares of Cencora in a research report on Wednesday, April 8th. Twelve equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $374.00.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.